Intervention Review

Addition of drug/s to a chemotherapy regimen for metastatic breast cancer

  1. Daria J Butters2,
  2. Davina Ghersi3,
  3. Nicholas Wilcken4,
  4. Steven J Kirk5,
  5. Peter T Mallon1,*

Editorial Group: Cochrane Breast Cancer Group

Published Online: 10 NOV 2010

Assessed as up-to-date: 9 AUG 2009

DOI: 10.1002/14651858.CD003368.pub3

How to Cite

Butters DJ, Ghersi D, Wilcken N, Kirk SJ, Mallon PT. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD003368. DOI: 10.1002/14651858.CD003368.pub3.

Author Information

  1. 1

    Institute of Clinical Science, Department of Surgery, Belfast, Northern Ireland, UK

  2. 2

    Footscray, Victoria, Australia

  3. 3

    University of Sydney, School of Public Health, Camperdown, Australia

  4. 4

    Westmead and Nepean Hospitals, Medical Oncology, Westmead, NSW, Australia

  5. 5

    Ulster Hospital, Belfast, Northern Ireland, UK

*Peter T Mallon, Department of Surgery, Institute of Clinical Science, Royal Victoria Hospital, Belfast, Northern Ireland, BT12 6BA, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 10 NOV 2010


Cited in:


This article has been cited by:

  1. 1
    Livio Garattini, Katelijne van de Vooren, Alessandro Curto, Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?, Health Policy, 2015, 119, 2, 212


  2. 2
    Zoya Cohen, Yair Maimon, Merav Yoeli-Lerner, Peiying Yang, Noah Samuels, Raanan Berger, Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: Implications for cancer treatment, International Journal of Oncology, 2014,


  3. 3
    Antonio Rossi, Valter Torri, Marina Chiara Garassino, Luca Porcu, Domenico Galetta, The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers, Cancer Treatment Reviews, 2014, 40, 4, 485